Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03160-4
Abstract: Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM). In our previous report, CD19- and BCMA-targeted CAR-T co-administration was associated with a high response rate. Although cytokine release syndrome… read more here.
Keywords: therapy; bcma targeted; antigen receptor; car ... See more keywords
Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.742.742
Abstract: Patients with relapsed/refractory MM (RRMM) rarely obtain durable remissions with available therapies. Clinical use of BCMA targeted CAR T cell therapy was first reported in 12/2015 for RRMM, and based on small numbers, preliminary results… read more here.
Keywords: targeted car; car cells; bcma targeted; cell ... See more keywords
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000466
Abstract: Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy. These observations suggest this patient population could be included in ongoing BCMA-targeted therapy trials. read more here.
Keywords: myeloma; serial treatment; targeted therapy; bcma ... See more keywords